Claude autonomously discovers novel CRISPR-like 'ART' enzyme system, Anthropic says

Anthropic says Claude found what it describes as a potential new gene-editing mechanism buried in bacterial genomes, recognizing a repeating DNA pattern alongside an accessory protein of unknown function that earlier bioinformatics work overlooked. CEO Dario Amodei posted that it represents 'a molecular machine that we suspect could represent a new gene editing mechanism,' while cautioning that 'its precise function, biotechnological utility (if any), or level of significance is not yet clear.' The result came out of the company's newly established biology research lab in San Francisco.

Mechanically, Claude worked through a large corpus of DNA sequences over about 21 hours, flagging the array-associated reverse transcriptase (ART) system by its structural pattern rather than by matching a known signature. Anthropic frames this as evidence that frontier models can surface genuine scientific candidates from data at a scale and speed impractical for human researchers, rather than merely summarizing existing literature.

The announcement lands the same week Anthropic loosened some biology safety guardrails via a Life Sciences Verification Program tied to Opus 5.5 — a juxtaposition critics find uncomfortable given escalating AI-safety fears elsewhere in the industry. Gizmodo noted pointedly that Anthropic 'can't say what it's capable of,' underscoring that a structural resemblance to CRISPR is not proof of gene-editing function.

Skeptics will want peer-reviewed wet-lab confirmation before treating ART as a real editing tool; a suggestive structural pattern is a hypothesis, not a validated enzyme. Still, as an AI-for-science proof point it resonated widely, drawing 760 points on Hacker News and nearly 29,000 likes on Amodei's post. Watch for whether independent labs can reproduce and characterize the ART system.